• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
 
  • Détails
Titre

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Annals of Oncology  
Auteur(s)
Petit, P.F.
Auteure/Auteur
Daoudlarian, D.
Auteure/Auteur
Latifyan, S.
Auteure/Auteur
Bouchaab, H.
Auteure/Auteur
Mederos, N.
Auteure/Auteur
Doms, J.
Auteure/Auteur
Abdelhamid, K.
Auteure/Auteur
Ferahta, N.
Auteure/Auteur
Mencarelli, L.
Auteure/Auteur
Joo, V.
Auteure/Auteur
Bartolini, R.
Auteure/Auteur
Stravodimou, A.
Auteure/Auteur
Shabafrouz, K.
Auteure/Auteur
Pantaleo, G.
Auteure/Auteur
Peters, S.
Auteure/Auteur
Obeid, M.
Auteure/Auteur
Liens vers les personnes
Pantaleo, Giuseppe  
Peters, Solange  
Bouchaab, Hasna  
Obeid, Michel  
Stravodimou, Athina  
Mederos Alfonso, Nuria Neisy  
Abdelhamid, Karim  
Latifyan, Sofiya  
Liens vers les unités
Immunologie et allergie  
Oncologie médicale  
ISSN
1569-8041
Statut éditorial
Publié
Date de publication
2025-01
Volume
36
Numéro
1
Première page
43
Dernière page/numéro d’article
53
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
The aim of this retrospective study was to evaluate the dual efficacy of tocilizumab (TCZ) in the treatment of immune checkpoint inhibitor (ICI)-associated arthritis (ICI-AR) and the prevention of relapses after rechallenge.
We identified 26 patients with ICI-AR. The primary objectives were to evaluate TCZ efficacy in ICI-AR treatment and as secondary prophylaxis during ICI rechallenge in 11 of them. Patients received prednisone (CS) at 0.3 mg/kg tapered at 0.05 mg/kg weekly for six weeks. TCZ was administered at a dose of 8 mg/kg every 2 weeks. In the subgroup receiving secondary prophylaxis (rechallenge n = 11), TCZ was reintroduced with the same regimen concurrently with ICI rechallenge, and without the addition of CS. A control group of patients (rechallenge n = 5) was rechallenged without TCZ. Secondary endpoints included post-rechallenge evaluation of ICI duration, reintroduction of CS >0.1 mg/kg/day, ICI-AR flares, and disease control rate.
The median age of the patients was 70 years. The median follow-up from ICI initiation was 864 days. Among the 20 patients treated with TCZ for ICI-AR, all (100%) achieved an ACR70 response rate, defined as greater than 70% improvement, at 10 weeks. Some 81% of these patients achieved steroid-free remission after 24 weeks on TCZ. The median follow-up period was 552 days in rechallenged patients. The results demonstrated a reduction in ICI-AR relapses upon ICI rechallenge in patients receiving TCZ prophylaxis compared with patients who did not receive prophylaxis (17% versus 40%). The requirement for CS was completely abolished with prophylaxis (0% versus 20%), and the mean duration of ICI treatment was notably extended from 113 to 206 days. The 12-month post-rechallenge outcomes showed a disease control rate of 77%. During TCZ prophylaxis, CXCL9 remained elevated, showing no decline from their concentrations at the onset of ICI-AR.
In addition to treating ICI-AR, TCZ demonstrated efficacy as a secondary prophylactic agent, preventing the recurrence of symptoms and lengthening ICI treatment duration after ICI rechallenge.
Sujets

Humans

Antibodies, Monoclona...

Antibodies, Monoclona...

Antibodies, Monoclona...

Female

Male

Immune Checkpoint Inh...

Immune Checkpoint Inh...

Immune Checkpoint Inh...

Retrospective Studies...

Aged

Middle Aged

Arthritis/drug therap...

Prednisone/administra...

Prednisone/therapeuti...

Neoplasms/drug therap...

Neoplasms/pathology

Aged, 80 and over

Recurrence

Adult

Secondary Prevention/...

arthritis

immune checkpoint inh...

irAEs

secondary prophylaxis...

tocilizumab

PID Serval
serval:BIB_0BA6393BFB37
DOI
10.1016/j.annonc.2024.08.2340
PMID
39241964
WOS
001412158300001
Permalien
https://iris.unil.ch/handle/iris/35333
Open Access
Oui
Date de création
2024-09-09T11:07:26.992Z
Date de création dans IRIS
2025-05-20T13:28:19Z
Fichier(s)
En cours de chargement...
Vignette d'image
Nom

TAPIR STUD ANNALS OF ONCOLOG 2024.pdf

Version du manuscrit

postprint

Licence

https://creativecommons.org/licenses/by-nc-nd/4.0

Taille

1.09 MB

Format

Adobe PDF

PID Serval

serval:BIB_0BA6393BFB37.P001

URN

urn:nbn:ch:serval-BIB_0BA6393BFB373

Somme de contrôle

(MD5):157ce988192e891d263e1f9b1659bc18

  • Copyright © 2024 UNIL
  • Informations légales